No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis

摘要: Background & Aims Patients with primary sclerosing cholangitis (PSC) are at increased risk for developing cholangiocarcinoma (CCA). PSC also can have inflammatory bowel diseases (IBDs) or features of autoimmune hepatitis (AIH), and therefore treated azathioprine. Azathioprine has been associated an malignancy, we investigated whether azathioprine use affects the CCA in persons PSC. Methods We performed a retrospective study well-defined patients using data collected from 3 large-volume, tertiary care centers Germany Norway. analyzed 638 (70% men; 5900 patient-years follow-up evaluation); 91 had received therapy (considered to be effective 90 days after first intake). Risk analysis was Cox proportional hazard model when risks competing end points were present. Results Of who treatment, 3.3% developed CCA, compared 6.8% without treatment. However, did not significantly affect (hazard ratio, 0.96; 95% confidence interval, 0.29–3.13; P  = .94). The only factor age 35 years older diagnosis 3.87; 1.96–7.67; Conclusions A Europe found no evidence that CCA. should withheld concomitant IBD and/or AIH.